Abstract
The analysis presented in the paper suggests an added value of radiomics features as prognostic and predictive biomarker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional information to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given the risk of overfitting.
View details
http://www.oraloncology.com/article/S1368-8375(17)30168-9/fulltext
Publication Date: Tuesday, June 27, 2017